OPU
PEAR

Omni Partners US’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Omni Partners US’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$6.61M Buy
+664,495
New +$6.57M 0.34% 50

Other funds holding PEAR

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Omni Partners US's PEAR Position: Q3 2021 in Review

Omni Partners US opened a new position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q3 2021: 664,495 shares worth $6.61M. The stake represents 0.34% of the portfolio and ranks #50 among its holdings.

85 funds tracked by Wall St. Rank hold PEAR as of Q3 2021.

  • Omni Partners US held 664,495 shares of Pear Therapeutics, Inc. Class A Common Stock worth $6.61M as of Q3 2021.
  • Pear Therapeutics, Inc. Class A Common Stock was a new Omni Partners US position in Q3 2021.
  • Pear Therapeutics, Inc. Class A Common Stock made up 0.34% of Omni Partners US's portfolio in Q3 2021, its #50 holding.
  • 85 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.